CTP Imaging for Lung Cancer Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing lung cancer, particularly in distinguishing between benign and malignant pulmonary nodules and identifying genetic mutations, are invasive, costly, and inefficient, leading to delayed targeted therapies and high mortality rates.
Innovation Solution
Computed tomography perfusion (CTP) imaging with dual-input pulmonary blood flow assessment provides non-invasive post-processing analysis to differentiate between lung malignancies with and without genetic mutations, potentially replacing genomic testing and enabling earlier targeted therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive procedures (biopsy, genomic testing) are used to identify genetic mutations, then diagnostic precision is improved, but patient harm and procedural complexity increase
Solution Approach 1:
The patent replaces invasive mechanical procedures (biopsy, surgical intervention) with non-invasive imaging technology (CT perfusion). The CTP technique measures blood flow parameters through contrast-enhanced imaging, eliminating the need for physical tissue sampling while providing diagnostic information about genetic mutations and lesion characterization.
Solution Approach 2:
The patent uses blood flow parameters as an intermediary to indirectly detect genetic mutations. Instead of directly analyzing tissue or DNA, the method measures hemodynamic characteristics (blood flow, blood volume, mean transit time) that reflect underlying genetic abnormalities, providing a non-invasive proxy for molecular characterization.
2Measurement precision
If invasive procedures and repeated CT exams are performed, then diagnostic accuracy is improved, but loss of time and increased cost occur
Solution Approach 1:
The patent combines multiple diagnostic functions into a single CTP examination. The technique simultaneously characterizes lesion vascularity, identifies genetic mutations, and differentiates between primary and metastatic disease in one procedure, eliminating the need for sequential biopsies, genomic testing, and repeated imaging over time.
Solution Approach 2:
The patent performs preliminary characterization of lesions using CTP parameters before proceeding to invasive procedures. By measuring blood flow, blood volume, and mean transit time in advance, the method identifies which lesions are likely to have specific genetic mutations, allowing clinicians to prioritize or avoid invasive testing based on imaging findings.
3Measurement precision
If repeated CT exams are performed to monitor lesions, then measurement precision is improved, but radiation exposure increases
Solution Approach 1:
The patent changes the imaging parameters from low-dose screening CT to perfusion-specific CT protocols with optimized contrast timing. By focusing on hemodynamic parameters (blood flow dynamics) rather than anatomical changes, the method achieves diagnostic precision with potentially reduced radiation exposure compared to repeated anatomical imaging over time.
4Measurement precision
If current diagnostic algorithms are used, then benign lesions are identified, but device complexity and procedural steps increase
Solution Approach 1:
The patent extracts the diagnostic information needed for lesion characterization directly from perfusion parameters without requiring complex multi-step algorithms. By measuring fundamental hemodynamic parameters (blood flow, blood volume, mean transit time), the method simplifies the diagnostic pathway while maintaining or improving accuracy compared to complex radiological algorithms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CTP imaging reduces the need for invasive procedures, lowers healthcare costs, and facilitates earlier and more personalized treatment by identifying genetic mutations, improving patient outcomes and reducing radiation exposure.
Implementation Method 1
Computed tomography perfusion (CTP) imaging with dual-input pulmonary blood flow assessment provides non-invasive post-processing analysis
Data Source
AI summary
Computed tomography perfusion (CTP) is used in a method to identify cancerous lesions having genetic mutations and treat them accordingly. Also, CTP values are used to distinguish primary versus metastatic lesions. For example, pulmonary blood flow is identified as one biomarker for EGFR and KRAS genetic mutations in lung cancer, lesion having dual-input pulmonary blood flow exceeding a threshold (e.g., 103 ml/min/100 mL with sensitivity 100% and specificity 62%) are determined as having mutations. The CTP values are calculated using a lesion region-of-interest (ROI) placed to include the area of maximum perfusion intensity within the lesion base and surrounding blush, while avoiding regions of perfusion inhomogeneity (e.g., due to necrosis). In certain implementations, instead of a binary determination, the method can generate probabilities associated with respective alternatives (e.g., mutation/non-nutation and/or primary/secondary), and the method can use multivariable statistical analysis that incorporates patient and/or medical information in addition to CTP values.